Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

It is a weighty problem. One in eight people across the world now have obesity, leaving them at higher risk of Type 2 diabetes, heart disease, arthritis, fatty liver disease, and certain cancers.

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

AquaSculpt is a breakthrough weight reduction product that claims to change the way people think about losing weight.

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a ...

the company believe their product can provide a 10-20 per cent weight loss with regular use. “A couple of years ago there was an article published in Nature about an exercise pill that was based ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Millions of Brits are now eligible for the appetite-suppressing jabs which can come with unpleasant side effects - but NHS rationing means only a tiny fraction will be prescribed them ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

Natural diet pills have become dominantly relevant these days since the obesity levels are rising every year. Losing and ...